Introduction
The peptides classically designated as calcitonin (CT) peptide family members include CT gene-related peptide (CGRP), amylin (AMY) and adrenomedullin (AM) (Poyner et al., 2002) , although an assortment of related peptides have recently been identified including intermedin (IMD), also known as AM2 (Katafuchi et al., 2003; Roh et al., 2004; Takei et al., 2004) . Whilst only weakly homologous in terms of amino acid sequence, several common features are shared, including an N-terminal ring structure that is the key to agonist activity. Nonetheless, the similarity in peptide structure leads to promiscuity for many of these peptides across their cognate receptors. Numerous biological activities have been attributed to these peptides. CT, for instance, is involved in bone homeostasis (Sexton et al., 1999) . AMY is likely to be involved in nutrient intake and regulating blood glucose levels (Cooper, 1994) .
CGRP and AM are both potent vasodilators, with AM necessary for vascular integrity (Hinson et al., 2000; Shindo et al., 2001; Brain and Grant, 2004) . As with many other peptides, significant advances in understanding the physiological, pathophysiological and clinical potential of CT family members are hampered by a lack of selective pharmacological agents that can be used to define function. Progress has been particularly slow for the CT peptide family as, until recently, the molecular nature of the cognate receptors for AMY, CGRP and adrenomedullin was unknown.
There is now some clarity regarding the nature of the receptor that likely mediates many of the effects of CGRP. It consists of a complex between a seven transmembrane protein belonging to the secretin family of G-protein coupled receptors (GPCRs), the CT receptor-like receptor (CL), with receptor activity modifying protein (RAMP) 1 (McLatchie et al., 1998) . When these proteins are coThis article has not been copyedited and formatted. The final version may differ from this version. (McLatchie et al., 1998; Hay et al., 2004) . However, if CL is instead co-expressed with either of the two other RAMP family members, RAMP2 or RAMP3, adrenomedullin is recognized most effectively (McLatchie et al., 1998) . Thus, RAMPs act as pharmacological switches.
It was soon realized that the function of RAMPs may be much broader and there are now several examples of secretin family GPCRs with which these proteins are likely to interact (Christopoulos et al., 1999; Christopoulos et al., 2003) .
Notably, RAMPs have a strong interaction with the CT receptor, the closest relative to CL (Christopoulos et al., 1999) . Together, RAMPs and the CT receptor generate receptors with high affinity for AMY, the precise nature of these receptors depending on the CT receptor splice variant and cellular background (Tilakaratne et al., 2000) . To our knowledge, there have been no other reports of a distinct molecular entity capable of responding to AMY with such high affinity. It is noteworthy that early attempts to clone the AMY receptor usually produced the CT receptor, thus it is likely that CT receptor/RAMP complexes mediate at least some of the effects of AMY in vivo although this has yet to be directly tested. Crucially, there is no reliable means of distinguishing CT from AMY receptors or AMY receptor subtypes pharmacologically in functional systems. Although comprehensive binding and agonist-interaction analyses have been performed, there has been no critical analysis of the way that antagonists interact with these receptors. This type of information may allow the different biological effects of AMY and related peptides to be attributed to distinct receptor subtypes. It can also provide a basis for the rational design of more selective agents. This is important since an AMY analogue (Pramlintide) has now reached late-stage development for glycaemic control in diabetic patients, illustrating the clinical importance of this peptide.
This article has not been copyedited and formatted. The final version may differ from this version. Therefore, in this study we have sought to address this issue by transfecting the CT receptor (CT (a) , Poyner et al., 2002) with, or without RAMPs into COS-7 cells that do not endogenously express phenotypically significant levels of RAMPs, CT receptors or CL. We have identified several key aspects of pharmacology that relate to the way that AMY and its related peptides have historically been reported to act in tissues.
This article has not been copyedited and formatted. The final version may differ from this version. performance liquid chromatography as previously described (Bhogal et al., 1992) . All other reagents were of analytical grade.
Expression constructs.
Double hemagglutinin (HA) epitope tagged human CT (a) receptor was prepared as previously described (Pham et al, 2004) . This receptor is the Leu 447 polymorphic variant of the receptor (Kuestner et al, 1994) . Human RAMP1, RAMP2
and RAMP3 and human CL receptor were a gift from Dr. Steven Foord (McLatchie et al, 1998) .
Cell culture and transfection.
COS-7 cells were subcultured as described previously (Zumpe et al., 2000) .
One day prior to transfection, COS-7 cells were seeded into 25cm 2 or 75cm 2 cell culture flasks at high density in order to achieve 90 -100% confluency for transfection the next day. The cells were then transfected using Metafectine, as per the manufacturer's instructions, with the following amounts of DNA: For 25cm 2 flasks, 1.25µg of receptor DNA (CT (a) or CL) and 1.9µg of RAMP or pcDNA3 DNA; for 75cm 2 flasks, 3.8µg of receptor DNA and 5.7µg of RAMP or pcDNA3 DNA. The transfection mix was removed after 16 hours incubation and the cells recovered in complete media (DMEM with 5% FBS) for 8 hours. The cells were then serumstarved for a further 16 hours in order to minimize basal cAMP levels.
Measurement of cAMP production.
Cells transfected with CT (a) or CL plus pcDNA3, RAMP1, 2 or 3 were harvested approximately 40 hours after transfection. The cells were counted and This article has not been copyedited and formatted. The final version may differ from this version. Following addition of lysis buffer, the plates were again centrifuged briefly to ensure thorough mixing. The cAMP in the lysed cells was assayed in the same wells using ALPHA-screen assay kits. A cAMP standard curve was included in each assay.
Briefly, cAMP was measured with acceptor and donor beads that were prepared in lysis buffer and added to the plates according to the manufacturer's instructions.
Following over night incubation in the dark, the plates were read with an ALPHAscreen protocol on a Fusion plate reader PerkinElmer (Boston, MA, USA).
Radioligand binding.
When harvested for cAMP assay (above), the same transfected COS-7 cells were also seeded into 24-well culture plates at a density of approx. parameter was shared across each family of curves to fits where each curve within a family was allowed its own Hill slope factor. The F-test was similarly used to determine whether the Schild slope was significantly different from unity within a given dataset. In the majority of instances, this was not the case, and thus all curves were re-fitted with the Schild slope constrained to a value of 1; under these conditions, the resulting estimate of pA 2 represents the pK B .
In all cases, potency and affinity values were estimated as logarithms (Christopoulos, 1998) . Data shown are the mean ± SEM. Comparisons between mean values were performed by unpaired t tests or one way ANOVA, as appropriate.
Unless otherwise stated, values of p < 0.05 were taken as statistically significant.
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Results
COS-7 cells were chosen for transfection studies as they have been shown to lack phenotypically significant levels endogenous RAMPs, CT receptors and CL (Hay et al., 2003) . Without significant background expression of such receptor components, defined receptor subtypes can be accurately compared.
Agonist pharmacology
The approach taken to generate a detailed pharmacological analysis of the molecularly defined AMY receptors was to compare the effects of all available antagonists against the major agonists that were capable of eliciting reliable receptor activation. Therefore, we initially examined agonist-induced cAMP responses in cells transfected with CT (a) alone, or in combination with individual RAMPs to assess the relative agonist activation profiles of the receptors defined as CT (a) , AMY 1(a) , AMY 2(a) and AMY 3(a) , respectively. In most experiments, cell surface expression of the CT (a) was confirmed by binding of an anti-HA antibody to the epitope tag incorporated into the N-terminus of the receptor ( Figure 2 ). In addition, in some experiments 125 I-sCT binding was also performed and confirmed that similar levels of the receptor protein were expressed at the cell surface (not shown). Expression of the AMY receptor phenotype was confirmed by concomitant 125 I-rAMY binding (data not shown).
As shown in table 1 Table 2 ). This contrasts with the interaction of IMDS at CGRP and AM receptors assayed in the same cellular background where IMDS displayed similar high efficacy at all three receptors but differed from the activity of hαCGRP at these receptors, which only had high potency at the CGRP 1 receptor ( Figure 3 ; Table 2 ).
The linear CGRP analogues (Cys(Et) 2,7 )-αCGRP and (Cys(Acm) 2,7
)-αCGRP have been used to sub-classify CGRP receptors into CGRP 1 and CGRP 2 receptors (Dennis et al., 1990; 1991; Poyner et al, 2002) . As AMY receptors can also function as high affinity CGRP receptors, it was of interest to assess the potency of the linear CGRP analogues at CT and AMY receptors. Both analogues had very low potency and efficacy at CT (a) , AMY 2(a) and AMY 3(a) receptors, but displayed moderate potency at the AMY 1(a) receptor (Table 1 ; Figure 4A ). However, both analogues were only partial agonists at the latter receptor exhibiting %E max responses of 47.9 ± 5.4 and 22.8 ± 6.0, respectively, for (Cys(Et) 2,7 )-αCGRP and (Cys(Acm) 2,7 )-αCGRP. At the CGRP 1 receptor, both analogues displayed high potency, pEC 50 9.4 ± 0.12 (n=5) and This article has not been copyedited and formatted. The final version may differ from this version. Figure 4B ).
Antagonist pharmacology
N-terminally truncated analogues of CT and related peptides have traditionally been used as "specific" antagonists of the primary receptors at which they interact.
However, the specificity of interaction across the range of CT and AMY receptor phenotypes has not been systematically addressed. We have therefore assessed the relative effectiveness of these peptide antagonists and a number of chimeras of sCT and rAMY ( Figure 1 ) as antagonists of CT (a) , AMY 1(a) and AMY 3(a) receptors.
Antagonist studies were not performed at the AMY 2(a) receptor because of the weak AMY phenotype we observe in COS-7 cells.
Of the peptides examined, sCT was the most effective antagonist with a pK B of ~8 across all receptors examined. It did not display significant selectivity, with a similar pK B observed for CT (a) , AMY 1(a) and AMY 3(a) receptors, for each of the agonists (Table 3; Intriguingly, there was an apparent agonist-dependent component to antagonism by CGRP 8-37 with no effect seen at any of the receptors when hCT was used as the agonist (Table 3 ; Figure 5B ; Figure 6B ; Figure 7B ).
In support of the weak effect of AM at these receptors (Table 1) , AM , an antagonist of AM receptors, had no effect at either CT or AMY receptors (Table 3) .
Confirmation of the integrity of AM 22-52 was obtained in experiments with AM 2 receptors, where this peptide is known to be an antagonist (data not shown, Hay et al., 2003) . rAMY 8-37 was almost without activity, exhibiting only very weak antagonist activity at AMY 1(a) receptors, and only when rAMY was the agonist (Table 3 ).
The peptide chimeras of rAMY and sCT 8-32 , AC187 and AC413, each had affinity for CT (a) , AMY 1(a) and AMY 3(a) receptors, but displayed selectivity between receptor phenotypes (Table 3 ; Figure 8C ,D). AC187 was ~10-fold more potent an antagonist of AMY 1(a) receptors compared with CT (a) receptors when rAMY was used as the agonist (Table 3 ; Figure 5G ; Figure 6G ; Figure 8C ). Similarly, AC187 was more potent at AMY 3(a) receptors over CT (a) receptors when rAMY was the agonist (Table 3 ; Figure 5G ; Figure 7G ; Figure 8C ), but no significant difference was seen between AMY 1(a) and AMY 3(a) receptors ( Figure 8C ). As seen with CGRP 8-37 , there was an apparent agonist-dependent effect observed with the antagonist potency of AC187 when hCT was the agonist, as no significant change in AC187 potency was seen across the 3 receptor types (Table 3 ; Figure 8C ). Equivalent antagonist behavior was observed for AC413 when hCT was the agonist, with no difference in antagonist potency between CT (a) , AMY 1(a) and AMY 3(a) receptors (Table 3 ; Figure 5D ; Figure   6D ; Figure 7D ; Figure 8D ). However, additional receptor-dependent and agonistThis article has not been copyedited and formatted. The final version may differ from this version. Figure 8D ), although this was not significant at the AMY 3(a) receptor. AC413 also appeared to discriminate between AMY 1(a) vs AMY 3(a) receptors when rAMY was used as the agonist, being more effective at AMY 1(a) ( Figure 8D ).
In competition for 125 I-rAMY binding, sCT , AC187 and AC413 each displayed high affinity at both AMY 1(a) and AMY 3(a) receptors, while CGRP 8-37 had lower affinity for both receptors (Table 4) . However, consistent with their lack of antagonist potency at AMY receptors, rAMY 8-37 and hAM 22-52 both exhibited very low affinity (Table 4) .
Discussion
Many factors alter the potency of agonists at GPCRs; affinity and intrinsic efficacy are receptor-dependent, while receptor density and G protein-coupling efficiency are system dependent (Armour et al, 1999; Kenakin, 1997) . In this study
we examined the effect of agonists and antagonists on CT and AMY receptors expressed at similar levels in the same cellular background to reduce systemdependent variables and to allow comparison of relative affinity and intrinsic efficacy of the agents used (Armour et al, 1999) .
As seen previously (Christopoulos et al, 1999 , Muff et al, 1999 , co-expression with RAMP3 than RAMP1, and is supported by the consistent reduction in CT potency with RAMP3 that is not seen with RAMP1 (Christopoulos et al, 1999 , Tilakaratne et al, 2000 Muff et al, 1999 , Armour et al, 1999 , Kuwasako et al, 2004 and also that only RAMP3 is able to induce an AMY receptor phenotype in melanophores (Armour et al, 1999) . However, it is also possible that hCT has lower efficacy at AMY 3(a) versus AMY 1(a) receptors.
Initial studies with IMDS indicated that it could interact, with similar potency, with CGRP and AM receptors (Roh et al, 2004) . We have confirmed this observation.
Its efficacy was equivalent to that of hαCGRP but there were marked differences in the relative potency of these two peptides for individual CL/RAMP combinations.
However, at CT (a) -based receptors, the activity of IMDS tracked that of hαCGRP.
This suggests that the IMDS binding interface at CT (a) -based receptors is similar to that of the CGRPs and contrasts to its mode of interaction with CL-RAMP receptors.
In our COS-7 cell background, the overall potency of IMDS was weaker at CT-based receptors than at CL/RAMP receptors, suggesting that the physiological target of IMDS is more likely to be the latter receptor family. During the preparation of this manuscript, a study examining the effect of IMD at CT (a) -based receptors in COS-7 cells was published, with similar findings to ours (Takei et al., 2004) .
Unlike agonist behavior, antagonist potency is viewed as a receptor-dependent variable and so antagonists are the preferred tool for defining receptor subtypes (Christopoulos and El-Fakahany, 1999) . We have delineated the pharmacology of This article has not been copyedited and formatted. The final version may differ from this version. (Christopoulos and Kenakin, 1992) . Unlike AC187, which has only 2 amino acids of rAMY substituted into the sCT 8-32 backbone, AC413 is also homologous to rAMY over residues 8-18 (Figure 1) and so may interact with higher affinity at the site occupied by rAMY versus that occupied by hCT. Alternatively, each of the agonists may provide a unique receptor conformation, leading to alteration in system dependent activity of the receptor that is manifest as differential antagonist affinity. However, we believe this is less likely, as such changes could be expected to alter affinity of other antagonists.
In contrast to the N-terminally truncated peptides already described, rAMY was essentially without antagonist activity at any of the receptors, consistent with its low affinity in competition binding studies ( )-αCGRP were partial agonists, in contrast to the data of Kuwasako et al (2004) . It is highly likely that this discrepancy may be explained by the HEK293 cells used by Kuwasako and colleagues having more efficient receptor coupling to G-proteins, masking partial agonist behavior. In support of this, αCGRP was also much more potent in their study. It is also significant that Kuwasako et al showed that there was relatively little difference in the dissociation constants for CGRP and the two cys-modified analogues as measured in binding studies; a consistent theme in the literature has been the failure to observe a CGRP 1 /CGRP 2 difference using radioligand binding (e.g Dennis et al., 1990) . In the porcine aorta, (Cys(Acm) 2,7 )-αCGRP was a partial agonist (Waugh et al., 1999) .
In summary, despite the complicated pharmacology of CT/RAMP complexes there are several useful tools in defining these receptors including agonists (rAMY, hCT) that are specific for CT and AMY receptor subtypes and antagonists (sCT 8-32 , AC187, CGRP ) that used in conjunction can help define these receptor classes.
Individual receptor subtypes, such as AMY 1(a) and AMY 3(a) receptors, can also be This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. The graph is of a representative experiment, with triplicate repeats, of at least 6 independent experiments.
Figure 4
Induction of cAMP accumulation at AMY 1(a) (A) 
Figure 7
Representative antagonist curves at AMY 3(a) receptors; sCT 8-32 (A, E), CGRP 8-37 (B, This article has not been copyedited and formatted. The final version may differ from this version. )hαCGRP and (Cys(ACM) 2,7 )hαCGRP, respectively. These values were generated by comparing the curve maximum asymptotes of the hαCGRP analogues with that for hαCGRP itself (set at 100%), which was used as the reference full agonist for these experiments.
b E max values for IMDS were equivalent to those of hαCGRP assayed in parallel.
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